Vetoquinol is a French veterinary pharmaceutical company that specializes in the development, manufacturing, and distribution of veterinary drugs and products. Headquartered in Lure, France, the company was founded in 1933 by veterinarian Joseph Frechin and started its operations by producing and distributing veterinary vaccines and pharmaceuticals. Vetoquinol offers a wide range of products and services in various therapeutic areas, including anti-infectives, anti-inflammatories, dermatology, and cardiology.

The company's product portfolio includes antibiotics, vaccines, antiparasitics, supplements, and other specialty pharmaceuticals for various animals such as dogs, cats, horses, cows, pigs, and poultry. Vetoquinol also provides technical support and educational materials to veterinarians and animal owners. With a global presence, Vetoquinol operates in over 100 countries worldwide.

The company has established several noteworthy subsidiaries, joint ventures, and partnerships to expand its operations and reach. It has subsidiaries in countries like the United States, Brazil, Canada, Australia, and numerous European countries. Additionally, Vetoquinol has partnerships and distribution agreements with various regional players to expand its market access.

Vetoquinol holds a prominent market position in the veterinary pharmaceutical industry. It consistently generates significant global sales and competes against other major players in the field. The company has a strong brand reputation and a comprehensive product portfolio, allowing it to maintain a competitive edge.

In terms of major events and achievements, Vetoquinol has made significant strides in its growth strategy. The company has focused on expanding its global footprint through acquisitions, partnerships, and the development of innovative products. In recent years, Vetoquinol has also made efforts to enhance its digital capabilities to provide better customer experiences and support to veterinarians and animal owners.

As of the latest available information, Vetoquinol continues to thrive as a leading veterinary pharmaceutical company. The company remains committed to providing high-quality products and services to its global customer base. It constantly innovates and adapts to meet the evolving needs of the veterinary industry